🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Beta-Blocker Interruption or Continuation after Myocardial Infarction 🧑‍🤝‍🧑3698 ▶️ 1846 to the 🔴interruption group and 1852 to the 🟢continuation group ⏰ between the last myocardial infarction and randomization was 2.9 years 📌A primary-outcome event occurred in 23.8% 🔴group

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the #FLOW trial #ESCCongress 🧑‍🤝‍🧑3533 ⏰3.4 years. 📌Semaglutide ⬇️ CV death/MI/stroke by 18% with consistency across eGFR categories, UACR levels and KDIGO risk classification

Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure Post Hoc Analysis of the #PARADIGM-HF and #PARAGON-HF 👥13 194 ⏰ 2.5 (1.8-3.1) years 👉Sacubitril/valsartan significantly ⬇️ 8% risk of all-cause 🏥 (ACH) 🆚 RASi 👉NNT of 48 patient-years of

#PREMIER trial In-🏥 initiation of angiotensin receptor–neprilysin inhibition in acute heart failure 👥 400🇯🇵(median age 75 years, 31.9% women, de novo heart failure rate 55.6%, and median EF 37%) 👉% changes in NT-proBNP level geometric means at Weeks 4/8 were −35%/−45%

📍Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation 👥 210 ⏰1 year, 👉at least one of the components of the primary efficacy end point occurred in 16.7% in the intervention group 🆚 22.5% in the surgery group 👉primary safety end-point

Si tú paciente está anticoagulado y se va a implantar TAVI, mantener ACO no es inferior a retirada #POPular PAUSE TAVI 👥858 📍💀CV/stroke/AMI event occurred 🟢16.5% in the continuation group 🔴14.8% in the interruption group 🩸Bleeding occurred in 🟢31.1% in the

🔴Asundexian versus Apixaban in Patients with Atrial Fibrillation #OCEANIC-AF 👥14810 with atrial fibrillation at risk for stroke ⏰over 11 months 🌏. 👉Asundexian 50 mg once daily was inferior for prevention of stroke and systemic embolism 🆚 Apixaban 📍The majority of

Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease 👥524 to the edoxaban monotherapy group 🆚 516 patients to the dual antithrombotic therapy 🇰🇷 ⏰12 months 👉 primary-outcome 6.8% assigned to edoxaban monotherapy 🆚 16.2% assigned to dual

🔴🔴Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction ⏰32 months 👉Finerenone ⬇️16%RR primary endpoint (CV💀/WHF) ⬇️12%RR total number of worsening heart failure events. 🔴No significant difference in CV💀 ⬆️ risk of hyperkalemia and a reduced

💡Que aporta FINEARTS-HF? ICP/ICmrEF, finerenona 👇👇 ⬇️ el riesgo de 💀CV e IC total ⬇️ los eventos de IC, ⬇️ los eventos de IC total ⬆️ estado de salud general 🟢resultados consistentes en todos los subgrupos preespecificados, incluida la FEVI y los 👥 tratados con SGLT2i

Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in #PARAGON-HF trial 👥 4795 ➡️23.2% had anaemia at randomization and 5.6% were treated with iron at baseline. ⏰median follow-up of 2.9 years 👥with anaemia were at significantly ⬆️ risk for total HF🏥

✅After #ESCCongress we are facing a #HFpEF revolution‼️ ➡️From now a triple or quadruple therapy (in case of obesity) will be the cornerstone of therapy ➡️We need a practical comprehensive approach for established & emergent #HFpEF treatments ↪️So this is Nicolas Manito proposal:

🔴Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER Via Nikhil Narang, MD 👥 11,007 DAPA-HF & DELIVER 📍primary outcome was the composite of worsening HF or CV💀 👥 12.4% were 🏥 for HF within 3 months of